{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T14:53:55Z","timestamp":1769525635306,"version":"3.49.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"french ministry of health","award":["MARVEL, 2015, P140935"],"award-info":[{"award-number":["MARVEL, 2015, P140935"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s40360-017-0173-2","type":"journal-article","created":{"date-parts":[[2017,11,7]],"date-time":"2017-11-07T06:52:25Z","timestamp":1510037545000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Exploring venlafaxine pharmacokinetic variability with a phenotyping approach, a multicentric french-swiss study (MARVEL study)"],"prefix":"10.1186","volume":"18","author":[{"given":"C\u00e9lia","family":"Lloret-Linares","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youssef","family":"Daali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvie","family":"Chevret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Nieto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fanny","family":"Moli\u00e8re","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Courtet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florence","family":"Galtier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rapha\u00eblle-Marie","family":"Richieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Morange","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre-Michel","family":"Llorca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wissam","family":"El-Hage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Desmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Haesebaert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Vignaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jer\u00f4me","family":"Holtzmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Luc","family":"Cracowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marion","family":"Leboyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoine","family":"Yrondi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabienne","family":"Calvas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liova","family":"Yon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Le Corvoisier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Doumy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyle","family":"Heron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damien","family":"Montange","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siamak","family":"Davani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julien","family":"D\u00e9glon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Besson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jules","family":"Desmeules","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"Haffen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Bellivier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,11,7]]},"reference":[{"issue":"386","key":"173_CR1","first-page":"743","volume":"9995","author":"Global Burden of Disease Study C","year":"2015","unstructured":"Global Burden of Disease Study C. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the global burden of disease study 2013. Lancet. 2015;9995(386):743\u2013800.","journal-title":"Lancet"},{"issue":"9","key":"173_CR2","first-page":"87","volume":"2","author":"P Sobocki","year":"2006","unstructured":"Sobocki P, Jonsson B, Angst J, Rehnberg C. Cost of depression in Europe. J Ment Health Policy Econ. 2006;2(9):87\u201398.","journal-title":"J Ment Health Policy Econ"},{"issue":"21","key":"173_CR3","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.euroneuro.2011.08.008","volume":"10","author":"A Gustavsson","year":"2011","unstructured":"Gustavsson A, Svensson M, Jacobi F, et al. Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011;10(21):718\u201379.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"68","key":"173_CR4","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.4088\/JCP.v68n0713","volume":"7","author":"D Souery","year":"2007","unstructured":"Souery D, Oswald P, Massat I, et al. Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. J Clin Psychiatry. 2007;7(68):1062\u201370.","journal-title":"J Clin Psychiatry"},{"issue":"9","key":"173_CR5","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0924-977X(98)00004-2","volume":"1-2","author":"D Souery","year":"1999","unstructured":"Souery D, Amsterdam J, de Montigny C, et al. Treatment resistant depression: methodological overview and operational criteria. Eur Neuropsychopharmacol. 1999;1-2(9):83\u201391.","journal-title":"Eur Neuropsychopharmacol"},{"key":"173_CR6","unstructured":"Kocsis JH. New strategies for treating chronic depression. J Clin Psychiatry 2000 61 Suppl 11):42\u20135."},{"issue":"63","key":"173_CR7","doi-asserted-by":"crossref","first-page":"963","DOI":"10.4088\/JCP.v63n1102","volume":"11","author":"WH Crown","year":"2002","unstructured":"Crown WH, Finkelstein S, Berndt ER, et al. The impact of treatment-resistant depression on health care utilization and costs. J Clin Psychiatry. 2002;11(63):963\u201371.","journal-title":"J Clin Psychiatry"},{"issue":"16","key":"173_CR8","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2174\/138920021601150702160728","volume":"1","author":"C Lloret-Linares","year":"2015","unstructured":"Lloret-Linares C, Bellivier F, Haffen E, et al. Markers of individual drug metabolism: towards the development of a personalized antidepressant prescription. Curr Drug Metab. 2015;1(16):17\u201345.","journal-title":"Curr Drug Metab"},{"key":"173_CR9","doi-asserted-by":"crossref","unstructured":"Hall-Flavin DK, Winner JG, Allen JD, et al. Using a pharmacogenomic algorithm to guide the treatment of depression. Transl Psychiatry. 20122:e172.","DOI":"10.1038\/tp.2012.99"},{"issue":"1","key":"173_CR10","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1159\/000430915","volume":"3","author":"CA Altar","year":"2015","unstructured":"Altar CA, Carhart J, Allen JD, Hall-Flavin D, Winner J, Dechairo B. Clinical utility of combinatorial pharmacogenomics-guided antidepressant therapy: evidence from three clinical studies. Mol Neuropsychiatry. 2015;3(1):145\u201355.","journal-title":"Mol Neuropsychiatry"},{"key":"173_CR11","doi-asserted-by":"crossref","unstructured":"Winner J, Allen JD, Altar CA, Spahic-Mihajlovic A. Psychiatric pharmacogenomics predicts health resource utilization of outpatients with anxiety and depression. Transl Psychiatry. 20133:e242.","DOI":"10.1038\/tp.2013.2"},{"issue":"31","key":"173_CR12","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1185\/03007995.2015.1063483","volume":"9","author":"JG Winner","year":"2015","unstructured":"Winner JG, Carhart JM, Altar CA, et al. Combinatorial pharmacogenomic guidance for psychiatric medications reduces overall pharmacy costs in a 1 year prospective evaluation. Curr Med Res Opin. 2015;9(31):1633\u201343.","journal-title":"Curr Med Res Opin"},{"issue":"8","key":"173_CR13","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1517\/17425255.2012.657626","volume":"3","author":"J McGraw","year":"2012","unstructured":"McGraw J, Waller D. Cytochrome P450 variations in different ethnic populations. Expert Opin Drug Metab Toxicol. 2012;3(8):371\u201382.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"44","key":"173_CR14","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1177\/0091270003261333","volume":"2","author":"H Zhou","year":"2004","unstructured":"Zhou H, Tong Z, McLeod JF. \"Cocktail\" approaches and strategies in drug development: valuable tool or flawed science? J Clin Pharmacol. 2004;2(44):120\u201334.","journal-title":"J Clin Pharmacol"},{"issue":"81","key":"173_CR15","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/sj.clpt.6100050","volume":"2","author":"U Fuhr","year":"2007","unstructured":"Fuhr U, Jetter A, Kirchheiner J. Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the \"cocktail\" approach. Clin Pharmacol Ther. 2007;2(81):270\u201383.","journal-title":"Clin Pharmacol Ther"},{"issue":"13","key":"173_CR16","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1097\/00008571-200310000-00003","volume":"10","author":"MD Floyd","year":"2003","unstructured":"Floyd MD, Gervasini G, Masica AL, et al. Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women. Pharmacogenetics. 2003;10(13):595\u2013606.","journal-title":"Pharmacogenetics"},{"issue":"9","key":"173_CR17","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/tpj.2008.7","volume":"1","author":"MC Rebsamen","year":"2009","unstructured":"Rebsamen MC, Desmeules J, Daali Y, et al. The AmpliChip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype prediction. Pharmacogenomics J. 2009;1(9):34\u201341.","journal-title":"Pharmacogenomics J"},{"issue":"28","key":"173_CR18","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1097\/01.ftd.0000246764.67129.2a","volume":"5","author":"T Heller","year":"2006","unstructured":"Heller T, Kirchheiner J, Armstrong VW, et al. AmpliChip CYP450 GeneChip: a new gene chip that allows rapid and accurate CYP2D6 genotyping. Ther Drug Monit. 2006;5(28):673\u20137.","journal-title":"Ther Drug Monit"},{"issue":"47","key":"173_CR19","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1176\/appi.psy.47.1.75","volume":"1","author":"J de Leon","year":"2006","unstructured":"de Leon J, Armstrong SC, Cozza KL. Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19. Psychosomatics. 2006;1(47):75\u201385.","journal-title":"Psychosomatics"},{"key":"173_CR20","doi-asserted-by":"crossref","unstructured":"Miller DB, O'Callaghan JP. Personalized medicine in major depressive disorder -- opportunities and pitfalls. Metabolism: clinical and experimental 2013 62 Suppl 1):S34\u20139.","DOI":"10.1016\/j.metabol.2012.08.021"},{"issue":"3","key":"173_CR21","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s40291-013-0028-5","volume":"17","author":"CF Samer","year":"2013","unstructured":"Samer CF, Lorenzini KI, Rollason V, Daali Y, Desmeules JA. Applications of CYP450 testing in the clinical setting. Mol Diagn Ther. 2013;17(3):165\u201384.","journal-title":"Mol Diagn Ther"},{"issue":"44","key":"173_CR22","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/clpt.1988.176","volume":"4","author":"E Steiner","year":"1988","unstructured":"Steiner E, Bertilsson L, Sawe J, Bertling I, Sjoqvist F. Polymorphic debrisoquin hydroxylation in 757 Swedish subjects. Clin Pharmacol Ther. 1988;4(44):431\u20135.","journal-title":"Clin Pharmacol Ther"},{"issue":"60","key":"173_CR23","first-page":"284","volume":"2","author":"C Sachse","year":"1997","unstructured":"Sachse C, Brockmoller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet. 1997;2(60):284\u201395.","journal-title":"Am J Hum Genet"},{"issue":"354","key":"173_CR24","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1056\/NEJMoa052963","volume":"12","author":"AJ Rush","year":"2006","unstructured":"Rush AJ, Trivedi MH, Wisniewski SR, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med. 2006;12(354):1231\u201342.","journal-title":"N Engl J Med"},{"issue":"373","key":"173_CR25","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/S0140-6736(09)60046-5","volume":"9665","author":"A Cipriani","year":"2009","unstructured":"Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet. 2009;9665(373):746\u201358.","journal-title":"Lancet"},{"issue":"15","key":"173_CR26","doi-asserted-by":"crossref","first-page":"643","DOI":"10.2165\/00023210-200115080-00007","volume":"8","author":"K Wellington","year":"2001","unstructured":"Wellington K, Perry CM. Venlafaxine extended-release: a review of its use in the management of major depression. CNS drugs. 2001;8(15):643\u201369.","journal-title":"CNS drugs"},{"issue":"44","key":"173_CR27","first-page":"195","volume":"6","author":"C Hiemke","year":"2011","unstructured":"Hiemke C, Baumann P, Bergemann N, et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry. 2011;6(44):195\u2013235.","journal-title":"Pharmacopsychiatry"},{"issue":"24","key":"173_CR28","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/FPC.0000000000000003","volume":"1","author":"K Sangkuhl","year":"2014","unstructured":"Sangkuhl K, Stingl JC, Turpeinen M, Altman RB, Klein TE. PharmGKB summary: venlafaxine pathway. Pharmacogenet Genomics. 2014;1(24):62\u201372.","journal-title":"Pharmacogenet Genomics"},{"issue":"20","key":"173_CR29","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/S0893-133X(98)00113-4","volume":"5","author":"SM Fogelman","year":"1999","unstructured":"Fogelman SM, Schmider J, Venkatakrishnan K, et al. O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants. Neuropsychopharmacology. 1999;5(20):480\u201390.","journal-title":"Neuropsychopharmacology"},{"issue":"22","key":"173_CR30","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/00007691-200004000-00011","volume":"2","author":"AH Veefkind","year":"2000","unstructured":"Veefkind AH, Haffmans PM, Hoencamp E. Venlafaxine serum levels and CYP2D6 genotype. Ther Drug Monit. 2000;2(22):202\u20138.","journal-title":"Ther Drug Monit"},{"issue":"32","key":"173_CR31","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/j.1552-4604.1992.tb03875.x","volume":"8","author":"KJ Klamerus","year":"1992","unstructured":"Klamerus KJ, Maloney K, Rudolph RL, Sisenwine SF, Jusko WJ, Chiang ST. Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active O-desmethyl metabolite. J Clin Pharmacol. 1992;8(32):716\u201324.","journal-title":"J Clin Pharmacol"},{"issue":"31","key":"173_CR32","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/j.1365-2710.2006.00763.x","volume":"5","author":"ME Shams","year":"2006","unstructured":"Shams ME, Arneth B, Hiemke C, et al. CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. J Clin Pharm Ther. 2006;5(31):493\u2013502.","journal-title":"J Clin Pharm Ther"},{"issue":"64","key":"173_CR33","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s00228-007-0453-7","volume":"5","author":"M Hermann","year":"2008","unstructured":"Hermann M, Hendset M, Fosaas K, Hjerpset M, Refsum H. Serum concentrations of venlafaxine and its metabolites O-desmethylvenlafaxine and N-desmethylvenlafaxine in heterozygous carriers of the CYP2D6*3, *4 or *5 allele. Eur J Clin Pharmacol. 2008;5(64):483\u20137.","journal-title":"Eur J Clin Pharmacol"},{"issue":"43","key":"173_CR34","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1046\/j.1365-2125.1997.00591.x","volume":"6","author":"SE Ball","year":"1997","unstructured":"Ball SE, Ahern D, Scatina J, Kao J. Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2. Br J Clin Pharmacol. 1997;6(43):619\u201326.","journal-title":"Br J Clin Pharmacol"},{"issue":"226","key":"173_CR35","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1016\/j.forsciint.2012.12.020","volume":"1-3","author":"J Jornil","year":"2013","unstructured":"Jornil J, Nielsen TS, Rosendal I, et al. A poor metabolizer of both CYP2C19 and CYP2D6 identified by mechanistic pharmacokinetic simulation in a fatal drug poisoning case involving venlafaxine. Forensic Sci Int. 2013;1-3(226):e26\u201331.","journal-title":"Forensic Sci Int"},{"issue":"33","key":"173_CR36","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/FTD.0b013e3181fcf94d","volume":"1","author":"DE McAlpine","year":"2011","unstructured":"McAlpine DE, Biernacka JM, Mrazek DA, et al. Effect of cytochrome P450 enzyme polymorphisms on pharmacokinetics of venlafaxine. Ther Drug Monit. 2011;1(33):14\u201320.","journal-title":"Ther Drug Monit"},{"issue":"87","key":"173_CR37","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1021\/ac503931g","volume":"4","author":"LA Leuthold","year":"2015","unstructured":"Leuthold LA, Heudi O, Deglon J, et al. New microfluidic-based sampling procedure for overcoming the hematocrit problem associated with dried blood spot analysis. Anal Chem. 2015;4(87):2068\u201371.","journal-title":"Anal Chem"},{"issue":"192","key":"173_CR38","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1192\/bjp.bp.106.032532","volume":"1","author":"JB Williams","year":"2008","unstructured":"Williams JB, Kobak KA. Development and reliability of a structured interview guide for the Montgomery Asberg depression rating scale (SIGMA). Br J Psychiatry. 2008;1(192):52\u20138.","journal-title":"Br J Psychiatry"},{"issue":"72","key":"173_CR39","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0165-0327(01)00451-7","volume":"2","author":"CJ Hawley","year":"2002","unstructured":"Hawley CJ, Gale TM, Sivakumaran T. Hertfordshire neuroscience research g. Defining remission by cut off score on the MADRS: selecting the optimal value. J Affect Disord. 2002;2(72):177\u201384.","journal-title":"J Affect Disord"},{"issue":"42","key":"173_CR40","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0920-9964(99)00130-9","volume":"3","author":"K Thompson","year":"2000","unstructured":"Thompson K, Kulkarni J, Sergejew AA. Reliability and validity of a new medication adherence rating scale (MARS) for the psychoses. Schizophr Res. 2000;3(42):241\u20137.","journal-title":"Schizophr Res"},{"issue":"15","key":"173_CR41","first-page":"535","volume":"6","author":"A Lesur","year":"1989","unstructured":"Lesur A, Bonnet D, Vicaut E, Lemperiere T. Tyrer's brief scale for anxiety used with outpatients. First validation in the French language. Enc\u00e9phale. 1989;6(15):535\u201342.","journal-title":"Enc\u00e9phale"},{"issue":"195","key":"173_CR42","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1192\/bjp.bp.108.061960","volume":"3","author":"R Uher","year":"2009","unstructured":"Uher R, Farmer A, Henigsberg N, et al. Adverse reactions to antidepressants. Br J Psychiatry. 2009;3(195):202\u201310.","journal-title":"Br J Psychiatry"},{"issue":"32","key":"173_CR43","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.genhosppsych.2009.07.009","volume":"1","author":"C Bryan","year":"2010","unstructured":"Bryan C, Songer T, Brooks MM, et al. The impact of diabetes on depression treatment outcomes. Gen Hosp Psychiatry. 2010;1(32):33\u201341.","journal-title":"Gen Hosp Psychiatry"},{"issue":"6","key":"173_CR44","doi-asserted-by":"crossref","first-page":"151","DOI":"10.4155\/bio.13.289","volume":"2","author":"M Bosilkovska","year":"2014","unstructured":"Bosilkovska M, Deglon J, Samer C, et al. Simultaneous LC-MS\/MS quantification of P-glycoprotein and cytochrome P450 probe substrates and their metabolites in DBS and plasma. Bioanalysis. 2014;2(6):151\u201364.","journal-title":"Bioanalysis"},{"key":"173_CR45","doi-asserted-by":"crossref","unstructured":"Bosilkovska M, Samer CF, Deglon J, et al. Geneva cocktail for cytochrome P450 and P-glycoprotein activity assessment using dried blood spots. Clinical pharmacology and therapeutics. 2014.","DOI":"10.1038\/clpt.2014.83"},{"issue":"163","key":"173_CR46","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1176\/appi.ajp.163.1.28","volume":"1","author":"MH Trivedi","year":"2006","unstructured":"Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;1(163):28\u201340.","journal-title":"Am J Psychiatry"},{"issue":"21","key":"173_CR47","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/00004714-200104000-00010","volume":"2","author":"I Schweitzer","year":"2001","unstructured":"Schweitzer I, Burrows G, Tuckwell V, et al. Sustained response to open-label venlafaxine in drug-resistant major depression. J Clin Psychopharmacol. 2001;2(21):185\u20139.","journal-title":"J Clin Psychopharmacol"},{"issue":"22","key":"173_CR48","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1177\/0269881107088441","volume":"4","author":"IM Anderson","year":"2008","unstructured":"Anderson IM, Ferrier IN, Baldwin RC, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol. 2008;4(22):343\u201396.","journal-title":"J Psychopharmacol"},{"key":"173_CR49","doi-asserted-by":"crossref","unstructured":"Rubin. Multiple imputation for nonresponse in surveys. Wiley online library. 1987.","DOI":"10.1002\/9780470316696"},{"key":"173_CR50","doi-asserted-by":"crossref","unstructured":"Little R. Statistical analysis with missing data, 2nd edition. Wiley 2002.","DOI":"10.1002\/9781119013563"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-017-0173-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,5]],"date-time":"2019-10-05T15:06:48Z","timestamp":1570288008000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-017-0173-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,7]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["173"],"URL":"https:\/\/doi.org\/10.1186\/s40360-017-0173-2","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,7]]},"article-number":"70"}}